Scientific and clinical resources for healthcare professionals
Inventiva Medical Affairs
Inventiva Medical Affairs supports scientific exchange and provides resources for healthcare professionals, researchers, and qualified stakeholders interested in MASH and lanifibranor.
About MASH
Metabolic dysfunction-associated steatohepatitis is a progressive liver disease associated with metabolic risk factors and significant long-term complications.
MASH can lead to fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma. It is also closely associated with cardiometabolic disease, including obesity, type 2 diabetes, and dyslipidemia.
Medical Affairs resources are intended to support balanced scientific exchange and help qualified audiences understand the evolving clinical landscape.
About Lanifibranor
Lanifibranor is an investigational pan-PPAR agonist being evaluated for the treatment of MASH.
Lanifibranor is designed to activate all three PPAR isoforms: alpha, delta, and gamma. This multimodal approach is intended to target pathways involved in inflammation, fibrosis, and metabolic dysfunction.
The safety and efficacy of lanifibranor have not been established by regulatory authorities. It remains an investigational therapy.
Lanifibranor is currently being studied in a Phase 3 clinical development program.
View Press ReleaseHow Lanifibranor Works
Clinical Trials
Inventiva is evaluating lanifibranor across clinical studies designed to understand its potential in MASH and related metabolic populations.
NATiV3 Clinical Trial
A pivotal Phase 3 study evaluating lanifibranor in MASH
NATiV3 is designed to assess the efficacy and safety of lanifibranor in adults with MASH and fibrosis.
Trial Design
Clinical Trial Sites
ClinicalTrials.gov
Previous Clinical Trials
NATIVE (Phase 2b)
24 weeks
Patient Population/Inclusion Criteria
Biopsy-proven MASH; SAF scores: Steatosis (1-3), Activity (3-4), Fibrosis (4).
Dose Cohorts & Patients (N)
800mg (N=83), 1200mg (N=83), Placebo (N=81); Total N=247.
Efficacy Results
1200mg: 45% MASH resolution (p<0.001) and 42% fibrosis improvement (p=0.013).
AEs/Safety
Mean weight gain: 2.7kg at 1200mg. Most events were mild or moderate.
